Pharmacology and Pharmacotherapeutics, 26e
- 26th Edition - December 7, 2020
- Authors: RS Satoskar, Nirmala Rege, SD Bhandarkar
- Language: English
- Paperback ISBN:9 7 8 - 8 1 - 3 1 2 - 5 6 9 5 - 4
- eBook ISBN:9 7 8 - 8 1 - 3 1 2 - 5 7 0 6 - 7
This book strengthens the scientific knowledge base and promotes rational thinking among students The Medical Council of India (MCI) has introduced a competency-based curriculum… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis book strengthens the scientific knowledge base and promotes rational thinking among students
The Medical Council of India (MCI) has introduced a competency-based curriculum in 2019, which not only lays emphasis on integration with clinical and pre-clinical subjects but also clearly states subject competencies and defines domains and levels to be achieved for each of them. In addition, it is clinically oriented and gives due importance to the self-directed learning. The duration of teaching for the subject of Pharmacology in the new curriculum has been reduced to one year with additional dedicated time to revisit it in the subsequent years. This 26th edition of Pharmacology and Pharmacotherapeutics has been revised considerably to match the demands of the new curriculum.
Right from its conception, this book has used an integrated approach intertwining current knowledge of pathophysiology of the disease, pharmacology of available drugs and strategies for medical management of diseases. We have made every attempt to provide up-to-date information about the drugs while focussing on the aspects relevant to their use in clinical practice.
- Structured pedagogy facilitating feature-rich presentation and organization of the content, which makes it more student friendly
- Richly illustrated content supplemented with large number of tables and boxes – explaining physiology, complex concepts, relevant drug features and principles of pharmacotherapy
- Mechanisms of drug actions, explained in text and illustrated via diagrams as well as videos (animations) for better understanding and retention
- Key points in pharmacology and pharmacotherapy of diseases highlighted throughout the book
- Practical tips in this book serve as a reference guide in practice so that students can treat their patients effectively and confidently
- Cover image
- Title page
- Table of Contents
- Copyright
- In memorium
- Preface to the Twenty sixth edition
- Preface to the first edition
- Acknowledgements
- Competency map
- Some abbreviations used in the text
- How to use
- List of Tables
- List of Illustrations
- Section 1. General Pharmacology
- 1. General considerations and pharmacokinetics
- The nature and sources of drugs
- Sources of drug information
- Routes of drug administration and dosage forms
- Absorption and bioavailability
- Distribution of a drug
- Fate of a drug
- Drug excretion
- Plasma half-life and its significance
- Methods of prolonging the duration of action of a drug
- Special drug delivery systems
- 2. Pharmacodynamics – drug receptor interactions; adverse drug reactions PH 1.1
- Site of drug action
- Structure activity relationship (SAR)
- Mechanism of drug action
- Drug receptors
- Dose–response relationship
- Response to drug combinations
- Adverse drugs reactions (ADR) PH 1.7
- Drug allergy
- Manifestations of ADR
- Management of ADR
- Treatment of acute drug poisoning
- 3. Principles of drug prescribing; factors modifying the effects of a drug; and drug interactions PH 1.1
- Drug prescribing
- P-drug (personal drug) concept
- Essential drugs PH 3.7, PH 1.59, CM 19.1
- Orphan drugs
- Factors modifying the effects of a drug
- Drug interactions
- 4. Drug invention , new drug development , and drug assay
- Animal toxicity studies
- Clinical evaluation
- Drug assay
- Section 2. Drugs Acting on the Central Nervous System
- 5. General considerations
- Drugs and CNS
- Neurochemical transmission in CNS
- CNS neurotransmitters
- 6. Aliphatic alcohols
- Acute alcohol intoxication
- Chronic alcoholism
- Alcohol tolerance
- Alcohol dependence (addiction)
- 7. General anaesthetics PH 1.18
- Inhalational general anaesthetics
- Volatile liquid anaesthetics
- Gaseous anaesthetics
- Nonvolatile general anaesthetics
- Neuroleptanalgesia
- Rational use of anaesthetic agents
- Preanaesthetic medication
- Drugs administered during anaesthesia AS 4.1
- 8. Sedatives, hypnotics and pharmacotherapy of sleep disorders
- Benzodiazepines
- Nonbenzodiazepine, benzodiazepine-receptor agonists
- Melatonin receptor agonists
- Orexin receptor antagonists
- Barbiturates
- Miscellaneous
- Pharmacotherapy of insomnia and other sleep disorders
- 9. Drugs effective in seizure disorders
- Types of epilepsy
- Antiepileptic drugs
- General principles of management of epilepsy
- Epilepsy and pregnancy
- Drug therapy of epilepsy (Table 9.2)
- AED in nonepileptic disorders
- 10. Opioid analgesics and antagonists
- Opium alkaloids
- Semisynthetic derivatives of natural opium alkaloids
- Synthetic morphine substitutes
- Nonanalgesic uses of opioids
- Opioid antagonists PH 1.19
- 11. Analgesic–antipyretics and nonsteroidal anti-inflammatory drugs (NSAIDs)
- Salicylates PH 1.16
- Pyrazolone derivatives
- Indoles and related drugs
- Heterocyclic arylacetic acid derivatives
- Propionic acid derivatives
- Fenamates
- Oxicams
- Preferential and selective COX-2 inhibitors
- Analgesic-antipyretic drugs
- Para-aminophenol derivatives
- Benzoxazocaine derivatives
- Pharmacotherapy of pain
- 12. Central nervous system stimulants
- Stimulants of the cerebral cortex
- Pharmacotherapy of narcolepsy
- Pharmacotherapy of attention-deficit hyperactivity disorder
- Stimulants of the brain stem and medullary centres
- Stimulants of the spinal cord
- Reflex stimulants of the central nervous system
- 13. Psychopharmacology – 1: Introduction, antipsychotic drugs, pharmacotherapy of psychosis and psychotogenic drugs
- Antipsychotic drugs
- Phenothiazine compounds
- Atypical antipsychotics (second generation)
- Management of schizophrenia
- Psychotogenic drugs
- Drug-induced psychiatric syndromes
- 14. Psychopharmacology – 2: Anxiolytics, antidepressants and pharmacotherapy of depression and manic-depressive psychosis
- Classification of antianxiety drugs
- Treatment of anxiety disorders
- Antidepressant drugs
- Monoamine oxidase inhibitors (MAOI)
- Tricyclic antidepressants (TCA)
- Selective serotonin reuptake inhibitors (SSRI)
- Treatment of major depression
- Mood stabilisers
- Manic depressive psychosis (MDP) – management
- 15. Drug therapy of parkinsonism and other neurodegenerative disorders
- Drug therapy
- MAO-B inhibitors
- COMT inhibitors
- Dopamine releasers
- Dopamine (D2) agonists
- Anticholinergics
- Miscellaneous
- Management of parkinsonism
- Drug therapy of other extrapyramidal syndromes
- Drug-induced extrapyramidal reactions (EPR)
- Motor neuron disease (MND) drug therapy
- Drugs and memory
- Multiple sclerosis (MS)
- Section 3. Local Anaesthetics
- 16. Cocaine, procaine and other synthetic local anaesthetics
- Section 4. Autonomic Nervous System
- 17. General considerations
- Distribution of parasympathetic nervous system
- Distribution of sympathetic nervous system
- Enteric nervous system (ENS)
- Neurohumoral transmission
- Neurohumoral transmitters
- Neurotransmitter uptake mechanisms and drugs PH 1.13
- 18. Adrenergic agonists and antagonists
- Catecholamines
- Noncatecholamines
- Other noncatecholamines
- Sympathetic blocking drugs PH 1.13
- Adrenergic receptor blockers
- 19. Cholinergic drugs
- Esters of choline
- Cholinomimetic alkaloids
- Cholinesterase inhibitors
- Organophosphorus compound (OPC) poisoning
- 20. Muscarinic receptor blocking drugs; pharmacotherapy of bladder dysfunction
- Belladonna alkaloids
- Synthetic and semisynthetic atropine substitutes PH 1.11
- Bladder dysfunction – pharmacology
- 21. Ganglion stimulating and blocking drugs; treatment of tobacco dependence
- Ganglion blocking agents
- 22. Skeletal muscle relaxants
- Centrally acting skeletal muscle relaxants
- Peripherally acting skeletal muscle relaxants
- Section 5. Other Biogenic Amines and Polypeptides
- 23. Histamine and antihistaminic drugs
- Histamine, anaphylaxis and allergy
- H1 receptor antagonists
- H2 receptor antagonists
- H3 and H4 receptors
- 24. 5-Hydroxytryptamine (serotonin), its agonists and antagonists; and treatment of migraine
- Pharmacotherapy of migraine
- 25. Angiotensin, kinins, leukotrienes, prostaglandins and cytokines
- Kinins
- Leukotrienes (LTS)
- Prostaglandins (PGs)
- Cytokines
- Section 6. Drugs Used in Respiratory Disorders
- 26. Pharmacotherapy of cough
- Pharyngeal demulcents
- Mucoactive drugs
- Central cough suppressants
- Peripherally acting agents
- Other antitussives
- 27. Pharmacotherapy of bronchial asthma, COPD and rhinitis
- I Bronchodilators (relievers)
- II Anti-inflammatory (controllers)
- Asthma management PH 1.1, CT 2.16
- Severe acute asthma (status asthmaticus) − treatment
- Management of COPD
- Surfactants and the respiratory distress syndrome
- Rhinitis-drug therapy
- Section 7. Cardiovascular Drugs
- 28. Pharmacotherapy of cardiac arrhythmias
- Class I: Fast sodium channel blockers
- Class II: Beta-adrenergic blockers
- Class III: Potassium channel blockers
- Class IV: Calcium channel blockers
- Class V: Miscellaneous
- Choice of antiarrhythmic agent
- Atrial fibrillation: Management
- Drugs used in the treatment of heart block
- 29. Pharmacotherapy of angina pectoris, acute MI and peripheral vascular diseases
- Nitric oxide (endothelium-derived relaxing factor – EDRF)
- Angina pectoris
- Drugs used in angina pectoris
- Organic nitrates
- Beta-adrenergic blocking agents
- Calcium channel blockers (CCB)
- Potassium channel activators
- Cytoprotectives
- Antiplatelet drugs
- Treatment of angina pectoris
- Acute coronary syndrome (ACS)
- Acute myocardial infarction (MI): Management IM 2.23, PH 1.28
- Drugs used in the treatment of peripheral vascular disorders PH 1.28
- 30. Pharmacotherapy of hypertension, pulmonary hypertension and orthostatic hypotension
- Thiazides as antihypertensives PH 1.24
- RAAS inhibitors PH 1.26, IM 11.18
- Calcium channel blockers (CCBs) IM 11.18
- Sympatholytic drugs
- Vasodilators
- Potassium channel activators
- Miscellaneous drugs
- Hypertension – therapy IM 8.14
- Aims of treatment of hypertension
- Principles of drug therapy PH 1.1
- Choice of drug therapy
- Use of drug combinations
- Management with drugs
- Hypertension in the elderly
- Hypertension in pregnancy
- Supportive treatment of hypertension
- Treatment of hypertensive crises IM 8.15
- Drug-induced hypertension
- Pulmonary hypertension
- Orthostatic hypotension
- 31. Pharmacotherapy of heart failure
- ACEI and vasodilators PH 1.26, IM 1.24
- Beta-adrenergic blockers IM 1.24
- Diuretics PH 1.24
- Aldosterone antagonists IM 1.24
- Digitalis and other inotropic agents IM 1.24
- Other inotropic agents
- Management of heart failure
- Diastolic dysfunction
- Nonpharmacological treatment of heart failure
- 32. Pharmacotherapy of shock
- Whole blood, plasma and plasma fractions
- Colloidal plasma expanders PH 1.25
- Crystalloid plasma expanders PH 1.25
- Cardiovascular drugs in shock
- Management of shock PH 1.1
- Section 8. Drugs Acting on Blood and Blood Forming Organs
- 33. Drugs and blood coagulation
- Antiplatelet agents
- Fast-acting anticoagulants
- II. direct thrombin inhibitors
- III. factor Xa inhibitors
- Slow-acting anticoagulants
- In vitro anticoagulants
- Fibrinolytic agents PH 1.25
- Fibrinolytic therapy
- Haemostatic agents
- Management of acute variceal bleeding
- Sclerosing agents
- 34. Drugs effective in iron deficiency and other related anaemias
- Iron metabolism (ferrokinetics)
- Pharmacotherapy of iron deficiency anaemia PH 1.35, IM 9.14, PE 13.5
- Treatment of iron poisoning FM 9.3
- Adjuvants to iron therapy
- Erythropoietin (EPO) and anemia PH 1.35
- 35. Drugs effective in megaloblastic anaemias, neutropenia and thrombocytopenia
- Drugs used in neutropenia PH 1.35
- Drugs used in thrombocytopenia
- 36. Drug-induced blood dyscrasias
- Section 9. Drugs Affecting Renal Functions
- 37. Diuretic and antidiuretic drugs, and drug-induced nephrotoxicity
- Diuretics
- Osmotic diuretics
- Xanthines as diuretics
- Carbonic anhydrase inhibitors
- Benzothiadiazines (thiazides)
- Loop diuretics
- Potassium-sparing diuretics
- Management of oedema PH 1.1
- Complications of diuretic therapy
- Acute renal failure (ARF) IM 10.25
- Antidiuretic agents PH 1.24
- Vasopressin receptor antagonists PH 1.24
- Drugs and nephrotoxicity
- Section 10. Drugs Used in Disorders of the Gastrointestinal Tract
- 38. Appetite stimulants, digestants, antiflatulents, appetite suppressants and hypolipidaemic agents
- Appetite stimulants
- Digestants PH 1.34, PH 1.61
- Antiflatulents and carminatives PH 1.34
- Anorexiants and treatment of obesity
- Atherosclerosis and hyperlipidemia
- Anti-hyperlipidemic/dyslipidemic drugs PH 1.31, IM 2.18, IM 11.18
- 39. Emetics, drug therapy of vomiting, vertigo and diarrhoea
- Emetics
- Drug therapy of vomiting
- Antihistaminic–antiemetic drugs
- Therapy of vertigo and dizziness
- Drug therapy of diarrhoea IM 6.13
- Chronic diarrhoea
- 40. Pharmacotherapy of constipation
- Anthraquinone group
- Irritant oils
- Miscellaneous stimulant laxatives
- Osmotic laxatives
- Bulk laxatives
- Emollient laxatives
- 5-HT4 receptor agonists
- Chloride channel activators
- Mu opoid receptor antagonists
- Management of constipation PH 1.1
- Treatment of haemorrhoids and anal fissure
- 41. Pharmacotherapy of peptic ulcer disease
- Antisecretory agents
- Mucosal protective drugs
- Gastric antacids
- Antacid therapy
- Management of peptic ulcer IM 15.15
- Section 11. Oxytocics and Uterine Relaxants
- 42. Pharmacology of ergot alkaloids, oxytocin, other oxytocics and uterine relaxants
- Ergot alkaloids
- Oxytocin
- Other oxytocics
- Uterine relaxants (tocolytics) PH 1.41
- Section 12. Chemotherapy
- 43. Sulphonamides, trimethoprim, cotrimoxazole, nitrofurans and quinolones
- Sulphonamides
- Cotrimoxazole
- Nitrofurans
- Quinolones
- 44. Penicillins and other antibiotics effective mainly against gram-positive organisms
- Semisynthetic penicillins
- Beta-lactamase inhibitors
- Macrolides
- Ketolide antibiotics
- Lincosamide antibiotics
- Glycopeptide antibiotics
- Miscellaneous antibiotics
- Streptogramins
- Oxazolidinones
- 45. Aminoglycosides and other antibiotics effective mainly against gram-negative organisms
- Nonaminoglycoside agents
- Monobactams
- 46. Antibiotics effective against both gram-positive and gram-negative organisms
- Cephalosporins
- Carbapenems
- Rifamycins
- Drug therapy of bacterial meningitis IM 17.13
- 47. Tetracyclines and chloramphenicol
- Tetracyclines
- Semisynthetic tetracyclines
- Chloramphenicol
- Pharmacotherapy of typhoid fever
- Pharmacotherapy of chronic bronchitis
- 48. Antifungal agents
- Azole derivatives
- Echinocandins
- 49. General principles of chemotherapy of infections PH 1.42
- Purpose of antimicrobial therapy
- Selection of antimicrobial agent PH 1.43
- Antibiotic use in the presence of organ dysfunction
- Antimicrobial combinations
- Antimicrobial prophylaxis
- Microbial drug resistance MI 1.6
- Risks of antimicrobial therapy
- Misuse of antimicrobial agents
- 50. Chemotherapy of urinary tract infections
- Drug therapy of UTI
- Treatment of lower UTI
- Treatment of upper UTI
- Antimicrobial prophylaxis
- 51. Chemotherapy of sexually transmitted diseases
- Drug therapy of syphilis
- Drug therapy of gonorrhoea
- Drug therapy of nongonococcal urethritis (NGU)
- Drug therapy of lymphogranuloma venereum
- Drug therapy of chancroid
- Drug therapy of granuloma inguinale
- Vaginitis – drug therapy
- Drug therapy of viral STD
- Drug therapy of HIV
- STD – prophylaxis
- 52. Chemotherapy of tuberculosis
- First-line drugs PH 1.44
- Second-line drugs PH 1.45
- Third-line drugs PH 1.45
- Newer drugs
- Management of pulmonary tuberculosis
- MDR tuberculosis management
- Other forms of tuberculosis OR 3.1
- Glucocorticoids in tuberculosis
- Chemoprophylaxis of tuberculosis
- Nontuberculous mycobacterial (NTM) infections
- Tuberculosis and HIV infection
- 53. Chemotherapy of leprosy
- Drugs used in leprosy
- Management of leprosy
- Leprosy prophylaxis
- 54. Chemotherapy of malaria
- 4-aminoquinolines
- 8-aminoquinolines
- Quinoline methanol
- Artemisinin compounds
- Cinchona alkaloids
- Phenanthrene methanol
- Biguanides
- Diaminopyrimidines
- Antimicrobials
- Management of malaria
- 55. Chemotherapy of amoebiasis
- Imidazole derivatives
- Quinoline derivatives
- Emetine group
- Antiamoebic antibiotics
- Miscellaneous agents
- Management of amoebiasis
- 56. Chemotherapy of other protozoal infections
- Visceral leishmaniasis or kala-azar
- Oriental sore
- Mucocutaneous leishmaniasis
- Trypanosomiasis
- Toxoplasmosis
- Trichomoniasis
- Giardiasis
- 57. Chemotherapy of viral infections
- Antiherpes and anti-CMV drugs
- Antihepatitis B drugs
- Antihepatitis C drugs
- Anti-influenza drugs
- Drugs against coronavirus
- Interferons
- 58. Chemotherapy of helminthiases
- Drug therapy of roundworms
- Drug therapy of hookworms
- Drugs therapy of pinworms
- Drug therapy of strongyloidiasis
- Drug therapy of trichuriasis (whipworm)
- Drug therapy of filariasis
- Drug therapy of guinea worm
- Drug therapy of tapeworms
- Drug therapy of schistosomiasis
- Drug therapy of tissue flukes
- 59. Chemotherapy of malignancy
- Alkylating agents
- Antimetabolites
- Radioactive isotopes
- Cytotoxic antibiotics
- Antimitotic natural products
- Hormones and antihormonal drugs
- Miscellaneous agents
- Monoclonal antibodies (mAb)
- Tyrosine kinase inhibitors
- Biological response modifiers
- Proteasome inhibitors
- Drug therapy of malignant diseases
- 60. Antiseptics, disinfectants and insecticides
- Physical agents
- Acids and alkalies
- Alcohols
- Aldehydes
- Surfactants
- Phenols and related compounds
- Halogens and halogen-containing compounds
- Oxidising agents
- Dyes
- Heavy metals
- Gases
- Choice of method of sterilisation and disinfection
- Insecticides
- Mosquito repellents
- Section 13. Drugs Used in Endocrine Disorders
- 61. Anterior pituitary hormones
- Endocrine physiology – introduction
- The pituitary gland
- Growth hormone inhibitors
- 62. Thyroid hormones and antithyroid drugs
- Treatment of myxoedema coma
- Iodine and the endemic goitre PH 1.37, PH 1.55, IM 12.13
- Antithyroid drugs PH 1.37
- Pharmacotherapy of hyperthyroidism
- Thyrotoxic crisis – treatment
- Iodine-containing contrast media
- 63. Pancreatic hormones, antidiabetic drugs and pharmacotherapy of diabetes mellitus
- Non-insulin antidiabetic drugs
- Oral antidiabetic agents
- Parenteral non-insulin antidiabetic agents
- Pharmacotherapy of diabetes mellitus
- III Management of emergencies in the diabetic III IM 11.18
- Hyperglycaemic agents
- Sweetening agents
- 64. Adrenal cortical steroids
- Adrenocorticotropin
- Hormones of the adrenal cortex
- Glucocorticoids and mineralocorticoids
- 65. Gonadotropins, estrogens and progestins
- Gonadotropins PH 1.37
- Estrogens
- Progesterone and other progestins
- 66. Antifertility agents and ovulation-inducing drugs
- Estrogen–progestin combination pill
- Progestins alone as contraceptives
- Anti-estrogenic agents
- Parenteral contraceptives
- Antiprogestins
- Postcoital contraception
- Male contraception
- Medical termination of pregnancy (MTP)
- Ovulation-inducing drugs
- Antigonadotropic compounds PH 1.37
- 67. Androgens, anabolic steroids, antiandrogens and treatment of sexual dysfunction
- Anabolic steroids PH 1.37
- Antiandrogens PH 1.37
- Management of hirsutism
- Benign prostatic hyperplasia (BPH)
- Sexual dysfunction
- 68. Calcium, phosphorus, fluoride and magnesium metabolism; parathyroid hormone and vitamin D; treatment of osteoporosis
- Phosphorus metabolism
- Synthetic vitamin D analogues
- Osteoporosis – management
- Fluoride
- Magnesium metabolism
- Section 14. Drugs Used in Common Skin and Eye Disorders
- 69. Pharmacotherapy of common skin disorders and skin protectives PH 1.57
- Principles of topical drug application PH 1.1
- Vehicles
- Formulations PH 1.3
- Choice of the preparation based on the skin lesion
- Keratolytic agents
- Pharmacotherapy of skin lesions PH 1.1
- Management of pruritus
- Drug therapy of bacterial and viral skin infections
- Drug therapy of fungal skin infections DR 8.7
- Dandruff and seborrhoeic dermatitis
- Drug therapy of scabies and pediculosis
- Drug therapy of acne vulgaris
- Drug therapy of allergic skin disorders
- Drug therapy of psoriasis
- Drug therapy of alopecia
- Drugs affecting skin pigmentation
- Sunscreens and barrier preparations
- Cosmetics, tooth powders and dermal fillers
- Anhidrotics and deodorants
- Drug-induced skin disorders
- 70. Ocular pharmacology
- Antimicrobial agents
- Anti-inflammatory drugs
- Glucocorticoids in the eye PH 1.38
- Antihistaminics and mast cell stabilisers PH 1.16
- Mydriatics and miotics PH 1.13, PH 1.14
- Drug therapy of glaucoma
- Immunosuppressives and antimitotic drugs PH 1.50
- Local anaesthetics PH 1.17
- Diagnostic agents
- Miscellaneous agents
- Drug-induced ocular toxicity
- Section 15. Immunopharmacology
- 71. General considerations: Vaccines and antisera
- Active immunisation
- Diptheria, tetanus and pertussis vaccines
- Passive immunisation
- Drug therapy of snake bite
- Drug therapy of scorpion sting PH 1.52, IM 20.8
- 72. Immunoglobulins, monoclonal antibodies, immunosuppressants and immunomodulators
- Monoclonal antibodies (mAb) in therapeutics
- Immunosuppressants SU 13.2
- Immunostimulants and immunomodulators PH 1.50
- Section 16. Miscellaneous
- 73. Pharmacotherapy of gout, rheumatoid arthritis and osteoarthritis
- Drugs used during acute stage
- Drugs used for correction of hyperuricaemia
- Xanthine oxidase inhibitors
- Uricosuric drugs
- Pharmacotherapy of rheumatoid arthritis (RA)
- Osteoarthritis IM 7.21, OR 3.1
- 74. Metals and their antagonists
- Heavy metal antagonists PH 1.53, FM 9.3
- 75. Gases: Therapeutic and toxic
- Therapeutic gases
- Hypoxia and hypoxaemia
- Management of hiccups
- Toxic gases PH 1.51, FM 9.6
- 76. Enzymes in therapy
- 77. Vitamins and antioxidants
- Fat-soluble vitamins
- Water-soluble vitamins
- Antioxidants PH 1.61
- 78. Drugs, pregnancy and the infant
- Pharmacokinetics during pregnancy
- Drugs, the fetus and the newborn
- Effects of drugs on pregnancy
- Teratogenicity
- Drug-prescribing during pregnancy
- Breastfeeding and drugs
- Appendix: Guide to further reading
- Illustration credits
- Index
- Flow charts of drug classifications
- No. of pages: 1160
- Language: English
- Edition: 26
- Published: December 7, 2020
- Imprint: Elsevier India
- Paperback ISBN: 9788131256954
- eBook ISBN: 9788131257067
RS
RS Satoskar
NR
Nirmala Rege
Seth GS Medical College and KEM Hospital, Parel , Mumbai - 400 012
SB